Log in   

Login to your account

CDR Blog

Official blog of CDR at University of Helsinki

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that has been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Login

European Technology Platform in Nanomedicine

Posted by on in Pharmaceutical Sciences
  • Font size: Larger Smaller
  • Hits: 739
  • Subscribe to this entry
  • Print
The University of Helsinki has appointed CDR Research Manager Paul Bromann to serve as the Finnish representative to the European Technology Platform in Nanomedicine (ETPN in short) Mirror Group. ETPN is an initiative led by industry and set up together with the European Commission in 2005 to address the applications of nanotechnology for breakthroughs in healthcare. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States. One of the main outcomes of this support is the elaboration and update of a Strategic Research Agenda (SRA) which serves as a reference for the EC to define their future calls. A recent outcome of the past nine months activities is the newly released White Paper, giving concrete recommendations and proposing a new set of infrastructures for nanomedicine in Europe under H2020.
The ETPN Mirror Group ensures the participation of Public Authorities at national, regional and European levels in their function as policy makers, regulators and funding bodies. The aim of the Mirror Group is to develop synergies between national programs and policies, pool resources to support the implementation of the SRA, and to promote a fertile innovation environment and a state-of-the-art research infrastructure in Europe. A key role is to facilitate the industrial academic interface from a European level down to regional levels. Mirror Group members have a broad view of the national programs and activities in the nanomedicine field, together with strong links with policy makers. They are official representatives of Member States authorities. They are in a position to establish strong links with national policy makers in order to reflect the state of the art of nanomedicine in the national programs and to disseminate strategic documents.
The list of countries represented in the ETP Nanomedicine Mirror Group is available here.
Last modified on

Paul Bromann received his Ph.D. in Neuroscience in 1999 (Northwestern University, Evanston, IL, USA) and completed postdoctoral fellowships at Washington University Medical School (Saint Louis, MO, USA) and Sanford-Burnham Medical Research Institute (San Diego, CA, USA). Dr. Bromann has extensive experience in protein engineering and also has several years of project management experience in academia as well as in industry. He served as Senior Scientist and Project Manager at NexBio, Inc./Ansun BioPharma (San Diego, CA, USA), where he led and managed a multi-disciplinary group project to develop a recombinant protein therapeutic, Sepcidin, to treat viral and inflammatory diseases. He also served as Research Scientist/Project Manager at VTT, Technical Research Centre of Finland. At VTT, Dr. Bromann internally managed a large EU project called Metaexplore, and led efforts to develop state-of-the-art metagenomics techniques for discovering and commercially exploiting novel enzymes for industrial applications. As part of the CDR’s commitment to developing novel biological and natural product drug discovery and pharmaceutical nanotechnology tools, Dr. Bromann serves as Research Manager for the CDR. He provides support to the Director in the development and management activities of the CDR including: promoting and coordinating collaboration with domestic and international industry, academia, and government agencies; and, the facilitation of patenting and technology transfer of CDR innovations.


  • No comments made yet. Be the first to submit a comment

Leave your comment

Guest Wednesday, 22 July 2015

From the Director

You must have the Adobe Flash Player installed to view this player.

Recent Activities